Curet Myriam - Apr 23, 2024 Form 4 Insider Report for INTUITIVE SURGICAL INC (ISRG)

Role
EVP & Chief Medical Officer
Signature
By: Donna Spinola For: Curet, Myriam
Stock symbol
ISRG
Transactions as of
Apr 23, 2024
Transactions value $
-$1,012,511
Form type
4
Date filed
4/24/2024, 01:18 PM
Previous filing
Mar 1, 2024
Next filing
May 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ISRG Common Stock Options Exercise $502K +2.82K +945.64% $177.99 3.12K Apr 23, 2024 Direct F1
transaction ISRG Common Stock Sale -$1.04M -2.82K -90.44% $370.66 298 Apr 23, 2024 Direct F1, F2
transaction ISRG Common Stock Options Exercise $457K +2.5K +838.93% $182.83 2.8K Apr 23, 2024 Direct F1
transaction ISRG Common Stock Sale -$927K -2.5K -89.35% $370.66 298 Apr 23, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ISRG Non-Qualified Stock Option (right to buy) Options Exercise $0 -2.82K -35.7% $0.00 5.08K Apr 23, 2024 Common Stock 2.82K $177.99 Direct F1, F3
transaction ISRG Non-Qualified Stock Option (right to buy) Options Exercise $0 -2.5K -33.33% $0.00 5K Apr 23, 2024 Common Stock 2.5K $182.83 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These shares were sold in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on August 12, 2024.
F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $368.86 to $371.98 as follows: 700 shares sold at $368.86 to $369.85; 3,321 shares sold at $369.99 to $370.94; and 1,297 shares sold at $371.03 to $371.98. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter.